| INTRODUCTION
Alpha-1-antitrypsin deficiency (AATD) is estimated to affect three million people worldwide, 1 with patients typically developing lower zone emphysema at a relatively young age. Point mutations lead to altered folding during alpha-1 antitrypsin biogenesis, and misfolded proteins form polymers that are retained within the endoplasmic reticulum of hepatocytes, rather than being systemically secreted. 2 In the lung, lack of alpha-1 antitrypsin permits uninhibited proteolytic damage to the connective tissue matrix, leading to emphysema in approximately 75% of PiZZ patients. 3 Liver disease occurs due to aggregation of alpha-1 antitrypsin polymers within the endoplasmic reticulum (ER) of liver cells, which form periodic acid-Schiff positive inclusions, a hallmark biopsy feature in AATDrelated liver disease. 4 Hepatocyte injury is believed to be related to ER stress, mitochondrial dysfunction, and triggering of autophagy, although the true pathophysiology is yet to be fully understood. 5 There is considerable variability in phenotypic expression in both liver and lung disease, 6 which is believed to reflect genetic 3 and environmental modifiers. 7 Cigarette smoking has been demonstrated to be the greatest predictor of lung function impairment in AATD cohorts 8 and smoking cessation is the most effective treatment strategy. 4 In children, AATD-related liver disease may present only transiently, being diagnosed after investigation for prolonged neonatal jaundice, whilst in others disease may persist, progressing to fibrosis and cirrhosis requiring childhood liver transplantation. 9 In adults liver disease has been reported in several cohorts or case series, with prevalence varying depending on the modality used to diagnose disease. In one study, clinical signs or symptoms suggestive of liver disease were reported in up to 63% of homozygous patients, 10 whereas other studies describe abnormalities of liver enzymes (eg alanine aminotransferase, ALT) in less than 10% of adult patients. 11, 12 Another paper published in 1986 reported biopsydefined fibrosis/cirrhosis in 17.5% of patients.
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Serum tests have also been investigated as possible predictors of significant liver disease with mixed results. [12] [13] [14] [15] Measurement of gamma-glutamyl transferase (GGT) may be of benefit, 16 but is possibly confounded by its probable relation to oxidative lung injury and airflow obstruction. 17 Tests intended to detect liver fibrosis are currently likely to be the most useful, such as the serum enhanced liver fibrosis (ELF) test 18 and/or transient elastography (which has a sensitivity of 71% and specificity of 91% using a cut off of 8 KPa to detect advanced fibrosis), 19 but more data in this cohort are needed.
The heterogeneity of liver disease in AATD implies that like lung disease, intrinsic factors such as genetics interact with environmental factors to determine clinical phenotype. Some studies have shown that heterozygosity for the Z allele (eg PiMZ) confers an increased risk of fibrosis or cirrhosis compared to the general population 16, 17 but it seems likely that cofactors such as alcohol consumption and non-alcoholic steatohepatitis (NASH) play a greater role in heterozygous forms of AATD. 20, 21 In this systematic review, the aims were to describe liver disease progression in AATD and assess the clinical effectiveness of liver transplantation.
| METHODS
Standard systematic review methodology aimed at minimising bias was employed. The main protocol was registered with PROSPERO (CRD42016040134).
| Searches
The search strategy is shared in the Data S1; it was initially broad and included the terms: alpha 1-antitrypsin deficiency, disease monitoring, disease progression, humans, liver, mortality and incidence. 
| Evidence synthesis
Narrative synthesis of evidence was undertaken for all included studies. We divided the synthesis into sub-groups of childhood and adult disease. Meta-analytic methods could not be employed due to heterogeneity of study design and outcomes.
| RESULTS
The PRISMA flow diagram in Figure 1 demonstrates the inclusion of papers related to prognosis and treatment of AATD. Participant characteristics and outcomes are summarised in Tables 1 and 2 respectively, with a more detailed description of relevant studies shown in Tables S5 and S6 . Records remaining from searches after removal of duplicates N = 2700 these studies were only included where the majority ( > 90%) of participants had polmerogenic AATD phenotypes (ie PiZZ, PiSZ).
| Risk of bias
There was a high risk of bias for the majority of the studies (Figures 2, 3 and Table S6 of the appendix). Nearly all were conducted retrospectively, and participants were often selected following clinical presentation with manifestations of AATD. The quality of reporting and conduct of the included studies was often low, especially among smaller, older studies. Participant characteristics were often poorly described, with baseline characteristics such as age, sex and ethnicity incompletely defined. Few studies included an appropriate control and for those that did, the composition of the control group varied widely. Follow-up was often incomplete and/or relatively short-term outcomes were reported, so that important outcomes such as mortality were not always included.
3.2 | Prognosis and outcomes in AATD-related liver disease
| Children
Twenty-eight papers reporting the prognosis and outcomes of children diagnosed with AATD under the age of 16 were reviewed (Table S5) .
A series of six papers reported the outcomes of 127 Swedish children identified at birth through screening and are recorded only once using data from the follow-up study at 16 years.
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T A B L E 2 Outcomes for children and adults with AATD 
Participant characteristics
There were a total of 1536 participants; characteristics were extracted from papers where they were adequately defined, and are summarised in Table 1 . Follow-up ranged from 3 months to 27 years.
Disease prevalence and progression
Only studies using definitive clinical end-points or requirement for liver transplantation were included, and the results are summarised in Table 2 . There were no reports of Hepatocellular carcinoma (HCC). Mortality was reported in 17 studies but overall mortality could not be reported due to data heterogeneity; mortality ranged from 0% in 10 children with PiZZ who presented with neonatal cholestasis followed up until 20 years of age, 28 to 25.5% in a cohort of 98 participants with PiZZ/PiSZ referred to a tertiary centre with liver disease. 29 Outcomes following liver transplantation are discussed in the treatment results section.
| Adults
Seven papers primarily reported the outcomes of adult populations 15, 16, [30] [31] [32] [33] [34] (Table S5 ). All studies reported outcomes in adulthood, but in three data was collected from presentation at birth until adulthood, whereas in the remaining papers follow-up was from adulthood until a maximum age of 68.
Participant characteristics
In total, there were 626 participants, characteristics are summarised in Table 1 . Different reporting styles precluded reporting of age for adults.
Disease prevalence and progression
Chronic liver disease in adults was adequately defined in five studies, 15, 16, 30, 31, 33 and 4 reported liver transplantation as an outcome;
the results are shown in Table 2 . Mortality was reported in four of the seven adult studies. As with the paediatric studies, there was significant heterogeneity between studies for age, phenotype and length of follow-up, so overall mortality could not be accurately | 881 which was liver-related. 33 However, 38% of these patients were found to be hepatitis C (HCV) carriers, and a further 40% have evidence of either current or previous Hepatitis B infection, and unsurprisingly viral infection was a risk factor for chronic liver disease in this study. 33 
| Factors associated with development of liver disease
Although a meta-analysis could not be performed, 12 paediatric and four adult studies investigated possible risk factors for the development of liver disease in subjects with AATD.
Children
In paediatric studies, neonatal hepatitis was believed to be a possible factor for the development of subsequent chronic liver disease in the study by Ghishan et al, 9 whilst Camarena et al reported that 44 .6% of those who had neonatal cholestasis died or underwent transplant, compared with no requirement for transplant for those that presented later in life. 35 In contrast, neonatal cholestasis was not found to be a risk factor for progression of liver disease in the studies by Nemeth et al. 28, 36 There are similarly conflicting results for serum markers. Francavilla et al found that in children requiring transplantation compared with those that did not, aspartate aminotransferase (AST) was significantly higher at presentation (P < 0.0001), and when combined with gamma-glutamyl transferase (GGT) also higher at 6 months (P < 0.001), 1 year (P < 0.0003) and 5 years (P < 0.01). 37 Pferdmenges also found that GGT at presentation was predictive of death or liver transplantation in infants. 13 However, serum AST at presentation was not noted to be a factor in the study by Filipponi et al, although this was an uncontrolled study of 16 children who all underwent liver transplantation. 12 Clinical jaundice and synthetic function have also been investigated as potential prognostic factors. Three studies found that raised bilirubin levels, in the "early stages" of the disease, 35 or at presentation 13,38 were a risk factor for future progression (P < 0.001 in the study by Pferdmenges et al), 13 while another study reported that prolonged jaundice ( > 6 months) in those presenting with neonatal hepatitis was more common in those who went on to require liver transplantation. 37 A retrospective study of 16 children referred for liver transplantation 12 suggested that recurrence of jaundice in children who present with neonatal cholestasis should be regarded as an alarm feature, although it is likely that this signifies deterioration in synthetic function. Of note, the study by Moroz et al found no correlation between jaundice and clinical outcomes, and although it included fewer patients than the other studies that followed up patients from presentation, no other reason for this difference could be identified. 39 Prolonged international normalised ratio (INR), a marker of synthetic function, was found to be a risk factor for poorer outcomes in the study by Pferdmenges (P < 0.001) when measured in "early disease," or at diagnosis in the study by Pfister (P < 0.001), with a similar, nonsignificant trend being seen in the study by Volpert.
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The same study by Volpert et al saw a trend for lower serum albumin at diagnosis in those that later developed cirrhosis, but the findings were not significant, 15 and not replicated in other studies, though for the majority of studies serum albumin was used as a marker of severity rather than investigated for prognostic purposes.
Adults
In adults, a possible increased risk of chronic liver disease in men was observed in a retrospective review of 19 individuals with AATD and liver disease, 32 and male gender was a risk factor (P = 0.006) for end-stage liver disease requiring liver transplantation in a retrospective follow-up of 139 individuals from a US AATD registry with selfreported liver disease. 34 In the same study, body mass index (BMI)
was also a risk factor (P = 0.01) for end-stage liver disease requiring liver transplantation. 34 Concurrent viral infection 33, 34 and increased alcohol intake 31, 34 have not consistently been shown to be risk factors or cofactors for development of liver disease in AATD.
Liver biopsy
Twelve paediatric and 1 adult study included biopsy findings; and seven studies attempted to correlate clinical outcomes with histological features. A summary of biopsy findings is in Table S5 . One retrospective review of 97 children referred to a liver transplant centre found that those who developed end-stage liver disease requiring transplantation were more likely to have bile duct proliferation (P < 0.01), severe fibrosis with bridging septa (P < 0.02), and established cirrhosis (P < 0.04) in biopsies taken at presentation, compared with those who had no requirement for transplantation. 37 Hadchouel et al also found that infants with AATD who presented with neonatal cholestasis who had bile duct proliferation and portal fibrosis at biopsy aged 1-6 months, showed a tendency to develop early cirrhosis and portal hypertension compared with those with predominant features of cholestasis, hepatocellular damage or ductular hypoplasia. 40 Portal fibrosis was also a risk factor for cirrhosis in children with AATD who presented with neonatal cholestasis at < 6 months (84.6% vs 26.3%, P < 0.01) in the study by Nebbia et al. 41 Paucity of bile ducts has also been suggested as a factor for poor prognosis. 12, 39 In the study by Nebbia et al, a higher proportion of children who later developed cirrhosis had this feature at biopsy before 6 months of age (31.6% vs 15.8% P = n.s), 12, 41 however, the difference between the groups was not significant, and other studies have not replicated these findings. [41] [42] [43] Rujner et al performed a case-control study to investigate whether serum procollagen III levels were associated with histological severity of fibrosis in individuals with AATD, but found no correlation. 44 
| Liver Transplantation for AATD-related liver disease
Although the initial search was designed to encompass all treatments for AATD, the only reported therapy in humans was liver transplantation. Twelve retrospective studies discussed liver transplantation as a treatment for AATD (Table S6) , six studies reported paediatric populations 12, 37, [45] [46] [47] [48] and six included both paediatric and adult patients.
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| Children
The studies included 425 children who underwent liver transplantation for AATD. Phenotypes were reported in 297 children; 95.6%
were PiZZ, with the remaining children having PiSZ, PiMZ, or unknown phenotypes. 60.5% were male, and median ages ranged from 1.9 to 6 years, with a full range of 1-17 years. Ethnicity was reported in two studies and 254 (97.2%) were described as Caucasian.
Only one study reported the indications for transplantation, with five studies reporting clinical features at the time of transplantation.
In 198 participants, ascites was reported in 89 (44.9%), jaundice in 48 (24.2%), varices or gastrointestinal bleeding in 78 (39.4%) and encephalopathy in 12 (6.1%). Outcomes following liver transplantation were reported in eight studies and are shown in Table S6 . Fiveyear survival ranged from 74% from transplant data in the 1980s 48 to 92% in two studies published since 2000. 37, 49 Most studies report an excellent quality of life in survivors, with no recurrence of AATD in the liver, no pulmonary complications, and favourable outcomes compared with other indications for liver transplantation.
| Adults
The studies included up to 656 adults who underwent liver transplantation for AATD. Phenotypes were reported in 130 participants, and were PiZZ in 96 (73.8%), and PiSZ in 24 (18.5%). A total of 74.0% participants were male, and median ages ranged from 34 to 54 years. A total of 93.1% of individuals were described as Caucasian. The indications for transplantation were not reported in sufficient numbers to draw conclusions.
Outcomes following liver transplantation are shown in Table S6 , and were included in four studies. Five-year survival was 80% in the most recent study published in 2013. 53 Survivors report an excellent quality of life, and had no recurrence of liver or lung disease. Only Only 10% of individuals with AATD develop cirrhosis, and 16.5% of children and 14.7% of adults who presented with AATD-related liver disease required transplantation. However, in children, it was observed that studies with longer follow-up appeared to have better long-term outcomes, suggesting that even those presenting with significant liver disease at a young age can fully recover if transplantation is not required. It is likely that this, in addition to ascertainment bias (most study data were reported from transplant centres), accounts for the discrepancy between the proportion of those with cirrhosis and those requiring transplantation.
Hepatocellular carcimona was not reported in children suggesting it is extremely rare. In adults, the overall incidence of 1.3% was similar to published data for aetiologies such as alcohol-related liver cirrhosis and primary biliary cholangitis. 54 A slightly higher incidence was recorded in one paper investigating patients with AATD, but this study included heterozygotes with concurrent hepatitis B and C, and the majority of HCC cases involved subjects with cirrhosis and viral liver disease. 55 Histological studies have associated cholangiocarcinomas and combined hepatocholangiocarcinomas with the PiZZ phenotype, but these were not reported in our follow-up studies. 56, 57 Mortality due to AATD-related liver disease in both children and adults has significantly declined since the late 1980s, when liver TOWNSEND ET AL.
| 883 transplantation became standard practice for end-stage liver disease secondary to AATD. Outcomes following liver transplantation for both paediatric and adult studies were excellent and comparable with other common indications for transplantation. 58 
| Limitations of the study
Unfortunately, heterogeneity of data and risk of bias was such that we were unable to perform a meta-analysis. The majority of studies were retrospective and there was significant selection bias; basic demographic data such as age and sex of participants was missing in several studies and long-term follow-up was often incomplete. In addition, many of the studies included heterozygous and/or nonpolymerogenic phenotypes and liver-related outcomes for these individu- 
